Less Than Half of Patients Prescribed New Cholesterol Drug Receive Insurance Approval
October 30, 2017
October 30, 2017
DALLAS, Oct. 30 -- The American Heart Association issued the following news release:
Less than half of patients received their insurer's approval for prescriptions of PCSK9 inhibitors, according to new research in the American Heart Association's journal Circulation.
PCSK9 inhibitors, like Repatha (evolocumab) and Praluent (alirocumab), work by increasing the removal of low-density lipoprotein (LDL) or "bad" cholesterol from the blood. They have been . . .
Less than half of patients received their insurer's approval for prescriptions of PCSK9 inhibitors, according to new research in the American Heart Association's journal Circulation.
PCSK9 inhibitors, like Repatha (evolocumab) and Praluent (alirocumab), work by increasing the removal of low-density lipoprotein (LDL) or "bad" cholesterol from the blood. They have been . . .